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Abstract
Background: Exposure to arsenic concentrations in drinking water in excess of 300 μg/L is associated
with diseases of the circulatory and respiratory system, several types of cancer, and diabetes; however,
little is known about the health consequences of exposure to low-to-moderate levels of arsenic (10–100
μg/L).
Methods: A standardized mortality ratio (SMR) analysis was conducted in a contiguous six county study
area of southeastern Michigan to investigate the relationship between moderate arsenic levels and twenty-
three selected disease outcomes. Disease outcomes included several types of cancer, diseases of the
circulatory and respiratory system, diabetes mellitus, and kidney and liver diseases. Arsenic data were
compiled from 9251 well water samples tested by the Michigan Department of Environmental Quality
from 1983 through 2002. Michigan Resident Death Files data were amassed for 1979 through 1997 and
sex-specific SMR analyses were conducted with indirect adjustment for age and race; 99% confidence
intervals (CI) were reported.
Results: The six county study area had a population-weighted mean arsenic concentration of 11.00 μg/L
and a population-weighted median of 7.58 μg/L. SMR analyses were conducted for the entire six county
study area, for only Genesee County (the most populous and urban county), and for the five counties
besides Genesee. Concordance of results across analyses is used to interpret the findings. Elevated
mortality rates were observed for both males (M) and females (F) for all diseases of the circulatory system
(M SMR, 1.11; CI, 1.09–1.13; F SMR, 1.15; CI, 1.13,-1.17), cerebrovascular diseases (M SMR, 1.19; CI, 1.14–
1.25; F SMR, 1.19; CI, 1.15–1.23), diabetes mellitus (M SMR, 1.28; CI, 1.18–1.37; F SMR, 1.27; CI, 1.19–
1.35), and kidney diseases (M SMR, 1.28; CI, 1.15–1.42; F SMR, 1.38; CI, 1.25–1.52).
Conclusion: This is some of the first evidence to suggest that exposure to low-to-moderate levels of
arsenic in drinking water may be associated with several of the leading causes of mortality, although further
epidemiologic studies are required to confirm the results suggested by this ecologic SMR analysis.
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Assessment of health risks associated with exposure to
moderately elevated levels of arsenic in drinking water
(10–100 μg/l) has become the subject of considerable
interest and some controversy in both regulatory and pub-
lic health communities. The National Research Council
(NRC) subcommittee on Arsenic in Drinking Water, for
instance, found that "additional epidemiological evalua-
tions are needed to characterize the dose-response rela-
tionship for arsenic-associated cancer and noncancer end
points, especially at low doses" [1](see page 3) and simul-
taneously concluded that the guideline of "50 μg/L does
not achieve...public health protection, and therefore,
requires downward revision as promptly as possible."
[1](see page 9). In the end, the United States Environmen-
tal Protection Agency (USEPA) recommended a reduction
in the maximum contaminant level (MCL) to 10 μg/l for
arsenic in US public drinking water supplies [2].
The call for a significant reduction in the MCL by the
USEPA was prompted, at least in part, by findings of inter-
nal cancers (especially bladder, kidney, liver, and lung)
among populations in Taiwan, Japan, Chile, and Argen-
tina that are exposed to elevated levels of arsenic (typically
> 300 μg/l) in their drinking water [3-8]. In addition to
cancer, ample evidence exists to support a relationship
between arsenic in drinking water and cardiovascular and
circulatory diseases such as blackfoot disease [9,10],
ischemic heart diseases [11], and cerebrovascular diseases
[12]. Emerging evidence also suggests an association
between arsenic and diabetes mellitus [13,14] and non-
malignant respiratory diseases [15,16]. Most of these stud-
ies, however, examined arsenic concentrations of 100 μg/
L and above, providing little insight into health effects
from low-to-moderate concentrations (10–100 μg/L)
which are more commonly found in sources of drinking
water in the US and Europe.
A few mortality studies have been conducted in areas
where arsenic concentrations in drinking water are com-
monly in the 10–100 μg/L range; however, a clear picture
of the relevant health risks has not yet emerged. Engel and
Smith (1994) conducted a standardized mortality ratio
(SMR) analysis for vascular and respiratory diseases in
thirty US counties with elevated levels of arsenic in drink-
ing water. Diseases of arteries, arterioles, and capillaries
(DAAC), emphysema, and chronic airways obstruction
exhibited significantly elevated SMRs in counties where
mean arsenic levels exceeded 20 μg/L. In a cohort mortal-
ity study in Millard County, Utah where arsenic levels
ranged from 14–166 μg/L, Lewis et al. [17] examined can-
cer and a host of cardiovascular, respiratory, and kidney
diseases. These authors reported significant positive SMRs
for women and men from hypertensive heart diseases,
and for only men from nephritis and nephrosis, and pros-
tate cancer. In contrast to the results from Engel and Smith
[10], however, Lewis et al [17] did not identify an elevated
SMR for DAAC, and did not investigate deaths caused by
emphysema or chronic airways obstruction. In ecologic
studies conducted in Belgium [18] and Hungary [19],
low-to-moderate levels of arsenic were not reported to be
associated with mortality due to diseases of the nervous
system, circulatory system, liver, or cancer. Individual-
level incidence studies of low-to-moderate arsenic expo-
sure have also generated ambiguous findings with regard
to the role of arsenic in cancers of the bladder and skin
[20-25].
In light of this uncertainty, it is important to continue to
investigate health risks from exposure to arsenic concen-
trations in the 10–100 μg/L range. Therefore, the goal of
this study is to investigate mortality rates for twenty-three
different health outcomes, including several types of can-
cer, circulatory and respiratory diseases, diabetes, and dis-
eases of the kidneys and liver in six contiguous counties of
Michigan with moderately elevated levels of arsenic in
drinking water.
Methods
Arsenic in southeastern Michigan study area
Elevated concentrations of arsenic in Michigan groundwa-
ter were first reported from a well supplying a mobile
home park in Huron County in 1981 [26]. Since then,
arsenic has been identified in groundwater supplies, typi-
cally in the 10–100 μg/L range, throughout six contiguous
counties of Michigan and is now a well-documented phe-
nomenon that has generated considerable concern [27-
29]. The counties involved include Genesee, Huron, Lap-
eer, Sanilac, Shiawassee, and Tuscola, and are located in
the Michigan thumb region (Figure 1). The 2000 US Cen-
sus indicates the six counties have a population of approx-
imately 740,000 people and occupy an area of
approximately 11,500 km2. The majority of the popula-
tion resides in Genesee County (439,000), while the
remainder is split fairly evenly among the other five coun-
ties (Table 1). Genesee County also contains the industrial
city of Flint and the largest proportion of African Ameri-
cans in the study area; in contrast, the other five counties
are predominantly rural and white.
Estimates of arsenic concentrations in drinking water in
the six-county study area were compiled from the Michi-
gan Department of Environmental Quality (MDEQ)
arsenic database which contains results from water sam-
ples collected and analyzed between 1983 and 2002. The
database includes 9,251 analyses of water samples from
the six-county study area, with another 23,691 analyses
conducted throughout the remainder of the state. This
database is comprised of samples analyzed using various
methodologies including graphite furnace atomic absorp-Page 2 of 11
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inductively coupled plasma (ICP) optical emission
hydride generation (1987–1988), hydride flame (quartz
tube AAS) (1989–1995), and ICP/mass spectrometry
(1996-present); previous analyses have indicated that
samples analyzed using different methods were highly
correlated [30]. Approximately 86% of the analyses were
of private wells, and 14% came from municipal wells.
Analyses of water samples from private wells were per-
formed at the request of property owners.
Using the MDEQ arsenic database, county-level mean and
median arsenic concentrations were calculated for private
wells. In addition, arsenic estimates were compiled for
each public well water supply in the area from the MDEQ
arsenic database [30]; those not drinking groundwater
were served by municipal surface water from the Great
The six-county study area in the "thumb" region of southeastern MichiganFigure 1
The six-county study area in the "thumb" region of southeastern Michigan.
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0.30 μg/L [31]. The size of the population served by pri-
vate well, public well, and public surface water supplies
was compiled from an MDEQ database and population-
weighted estimates were tabulated.
Mortality and population data
Cause-specific mortalities from 1979 to 1997 were com-
piled from Michigan Resident Death Files by the Vital
Records and Health Data Development Section of the
Michigan Department of Community Health (MDCH).
Twenty-three different underlying causes of death were
included in the study, categorized according to the Inter-
national Classification of Diseases, 9th Revision (ICD-9).
The twenty-three causes of death include several types of
cancer, diseases of the circulatory and respiratory system,
diabetes mellitus, and kidney and liver diseases, and are
listed in Table 2. Each of these diseases has shown some
evidence of association with arsenic exposure, although at
higher concentrations in drinking water. The number of
deaths from 1979 through 1997 by cause in each individ-
ual county and in the entire State were stratified by sex,
race, and age and grouped into five-year categories begin-
ning at age 35 and ending at ≥ 85 years of age. Census data
and population estimates were compiled at five-year time
intervals from the same period for the State of Michigan
and the six counties in the study area.
Data analysis
Sex-specific SMRs were calculated by dividing the number
of observed deaths from a given cause by the age- and
race-adjusted expected values for Michigan [32]. Expected
values were calculated using indirect adjustment;
statewide mortality rates for each underlying cause, strati-
fied by age, race, and sex were multiplied by the combined
sex-, race-, and age-specific person-years in each county.
To account for the large number of calculations (23 SMRs
each for males and females), 99% confidence intervals,
instead of 95%, were calculated. SMR analyses were con-
ducted for the entire six county study area, for only Gene-
see County (the most populous, urban, and racially
diverse county), and for the five counties besides Genesee.
Concordance of results across analyses was used to inter-
pret the findings.
Results
The six county study area contains a population-weighted
mean arsenic concentration of 11.00 μg/L and a popula-
tion-weighted median of 7.58 μg/L. In comparison, in the
remainder of Michigan, the population-weighted mean is
2.98 μg/L with a median of 1.27 μg/L (Table 1).
SMRs are reported for twenty-three causes of death for
males and females in the six county study area of south-
eastern Michigan (Table 2). Observed deaths from cancers
were not different from the expected values for males or
females, with the exception of cancer of the female repro-
ductive organs (ICD-9 179–184), which was elevated.
Deaths from all diseases of the circulatory system (ICD-9
390–459) and cerebrovascular diseases (ICD-9 430–438)
were elevated in both males and females. In females only,
deaths from atherosclerosis (ICD-9 440) were elevated
and deaths from aortic aneurysm (ICD-9 441) were
reduced. Deaths from respiratory diseases were elevated in
the study area, with chronic airways obstruction-related
deaths elevated in both males and females (ICD-9 496).
Males also experienced elevated mortality rates for all dis-
eases of the respiratory system (ICD-9 460–519). Deaths
from diabetes mellitus (ICD-9 250) and kidney diseases
(ICD-9 580–589) were also elevated among both males
and females in the study area. Deaths from chronic liver
diseases and cirrhosis (ICD-9 571) were reduced for males
and females.
In Genesee County alone, mortality rates were elevated for
the same health outcomes as those identified from the six
Table 1: Exposure and Population Statistics for Counties in Southeastern Michigan Study Area
Genesee 
County
Huron 
County
Lapeer 
County
Sanilac 
County
Shiawassee 
County
Tuscola 
County
Six Counties 
Combined
Remainder 
of Michigan
Number of Groundwater Samples Analyzed 2,768 2,068 2,419 729 822 445 9,251 23,691
% of Population Drinking Groundwater 50% 84% 82% 95% 100% 100% 68% 44%
Population-weighted Mean Arsenic Concentration (μg/L) 10.42 12.21 19.26 9.97 6.66 8.08 11.00 2.98
Population-weighted Median Arsenic Concentration (μg/L) 8.48 3.50 11.98 4.61 3.91 3.32 7.58 1.27
Population Size 430,459 34,951 74,768 39,928 69,770 55,498 705,383 8,589,914
White Race (%) 78% 99% 98% 98% 98% 97% 86% 74%
Residing in a Rural Area (%) 21% 90% 86% 100% 66% 88% 44% 30%
Lived in Same County 5 Years Earlier (%) 90% 89% 78% 82% 84% 85% 87% 83%
Population (above age 25) with at Least a Bachelor's Degree 13% 9% 9% 8% 10% 8% 11% 17%
Persons Below Poverty Level (%) 16% 15% 8% 14% 11% 13% 14% 13%
Median Household Income $31,030 $21,852 $35,874 $23,107 $30,283 $27,374 $30,332 $31,020
Arsenic data collected from 1983–2002, provided by Michigan Department of Environmental Quality.
US Maximum Contaminant Limit for public drinking water supplies is 10 μg/L.
Population statistics from US Census, 1990.Page 4 of 11
(page number not for citation purposes)
Environmental Health 2007, 6:4 http://www.ehjournal.net/content/6/1/4county analysis (Table 3). In addition, elevated mortality
rates were observed for both males and females from tra-
chea, bronchus, and lung cancer (ICD-9 162), ischemic
heart diseases (ICD-9 410–414), and all diseases of the
respiratory system (ICD-9 460–519). Deaths were also
elevated for only males from non-melanoma skin cancer
(ICD-9 173) and essential hypertension and hypertensive
renal disease (ICD-9 401, 403). Deaths from chronic liver
diseases and cirrhosis (ICD-9 571) were no longer signif-
icantly reduced for females.
In the five counties other than Genesee County, mortality
rates remained elevated for males and females from all
diseases of the circulatory system (ICD-9 390–459), cere-
brovascular diseases (ICD-9 430–438), diabetes mellitus
(ICD-9 250), and kidney diseases (ICD-9 580–589)
(Table 4). Deaths from chronic airways obstruction (ICD-
9 496) were no longer elevated. In fact, mortality rates
were significantly reduced for females from all diseases of
the respiratory system (ICD-9 460–519) and emphysema
(ICD-9 492). Deaths were also reduced for males and
females from trachea, bronchus, and lung cancer (ICD-9
162) and hypertensive heart disease and hypertensive
heart and renal disease (ICD-9 402, 404), for females
from ischemic heart diseases (ICD-9 410–414), and for
males from chronic liver diseases and cirrhosis (ICD-9
571).
Discussion
In these six county, five county, and Genesee county-only
SMR analyses of the Michigan thumb region, heightened
mortality rates were consistently observed for diabetes
mellitus, cerebrovascular diseases, and kidney diseases in
both males and females. Each of these health endpoints is
reported to be associated with arsenic in drinking water at
levels in excess of 200–300 μg/L; here we present some of
the first evidence of a relationship between these health
outcomes and arsenic concentrations in a region of the US
where elevated concentrations typically range from 10–
100 μg/L.
Arsenic has been shown to be associated with increased
rates of diabetes incidence [14], prevalence [13,33], and
mortality [8] in studies from Taiwan and Bangladesh.
Only one previous study, however, examined risk of mor-
tality from diabetes from drinking water arsenic concen-
trations below 200 μg/L and that study found no
association [17]. In contrast, we report elevated mortality
rates for diabetes in both males (SMR, 1.28; 99%CI, 1.18–
1.37) and females (SMR, 1.27; 99%CI, 1.19–1.35) (Table
Table 2: Standardized Mortality Ratios in Six County Southeastern Michigan Study Area, 1979–1997.
Cause of Death ICD-9 Males Females
Obs SMR 99% CI Obs SMR 99% CI
Cancers
Colon and rectum 153–154 1,439 1.04 0.97–1.11 1,369 1.03 0.96–1.10
Liver and biliary Passages 155–156 260 0.85 0.72–1.00 300 1.04 0.89–1.20
Trachea, bronchus and lung 162 4,425 1.02 0.98–1.06 2,297 1.02 0.96–1.07
Skin melanoma 172 143 0.99 0.79–1.22 91 0.97 0.73–1.27
Other skin cancer 173 59 1.24 0.86–1.72 26 1.06 0.60–1.72
Female reproductive organs 179–184 1,300 1.11* 1.03–1.19
Prostate 185 1,448 1.03 0.96–1.10
Bladder 188 348 0.94 0.82–1.08 171 0.98 0.80–1.19
Kidney and other urinary organs 189 325 1.06 0.91–1.22 194 1.00 0.82–1.20
Circulatory diseases
All diseases of the circulatory system 390–459 25,907 1.11* 1.09–1.13 26,699 1.15* 1.13–1.17
Essential hypertension and hypertensive renal disease 401, 403 203 1.16 0.96–1.38 250 1.01 0.85–1.18
Hypertensive heart disease and hypertensive heart and renal disease 402, 404 398 0.88 0.77–1.00 612 1.01 0.91–1.12
Ischemic heart diseases 410–414 14,073 1.01 0.99–1.03 12,573 1.01 0.98–1.03
Cerebrovascular diseases 430–438 3,493 1.19* 1.14–1.25 5,010 1.19* 1.15–1.23
Diseases of arteries arterioles and capillaries (DAAC) 440–448 1,220 1.01 0.93–1.08 1,329 1.04 0.97–1.11
Atherosclerosis 440 523 1.01 0.90–1.13 884 1.11* 1.02–1.21
Aortic aneurysm 441 504 0.95 0.85–1.07 212 0.81* 0.67–0.96
Respiratory diseases
All diseases of the respiratory system 460–519 4,433 1.05* 1.01–1.09 3,568 1.03 0.98–1.07
Emphysema 492 632 1.00 0.90–1.11 363 0.98 0.85–1.12
Chronic airways Obstruction 496 1,706 1.16* 1.09–1.24 1,134 1.14* 1.05–1.23
Other diseases
Diabetes mellitus 250 1,249 1.28* 1.18–1.37 1,612 1.27* 1.19–1.35
Chronic liver diseases and cirrhosis 571 632 0.67* 0.60–0.74 416 0.87* 0.77–0.99
Kidney diseases 580–589 614 1.28* 1.15–1.42 679 1.38* 1.25–1.52
ICD-9 = International Classification of Diseases, 9th Revision; Obs = Number of observed deaths; CI = confidence interval; *p < 0.01.Page 5 of 11
(page number not for citation purposes)
Environmental Health 2007, 6:4 http://www.ehjournal.net/content/6/1/42). This inconsistency may be explained by the added
power in our study which includes 1249 male and 1612
female deaths from diabetes, compared with only 20 male
and 35 female deaths in the Utah study by Lewis et al.
[17]. In addition, the Utah study relied on data from a
cohort of members of the Church of Jesus Christ of Latter-
day Saints whose personal lifestyle choices (e.g., no
tobacco smoking or consumption of alcohol) make com-
parisons with other study populations difficult. Diabetes
mellitus is a complex disease, defined as a set of abnor-
malities characterized by a state of sustained hyperglyc-
emia. It is the sixth leading cause of death in the United
States, with unknown specific etiology [34,35]. The fea-
tures of diabetes mellitus most commonly observed in
arsenic-exposed individuals are similar to non-insulin-
dependent diabetes mellitus or Type 2 diabetes [14].
Although the biological mechanisms responsible for
arsenic-induced diabetes mellitus are largely unknown,
recent evidence suggests that the trivalent arsenicals may
suppress insulin-stimulated glucose uptake by interfering
with mobilization of glucose transporters in adipose cells
[36], as well as interfering with transcription factors
involved in insulin-related gene expression [37].
Kidney diseases are the ninth leading cause of death in the
United States [35] and were also found to be elevated in
the six county study area for males (SMR, 1.28; 99%CI,
1.15–1.42) and females (SMR, 1.38; 99%CI, 1.25–1.52),
as well as in the five county and Genesee County-only
analyses. Elevated mortality rates for kidney diseases have
been reported in high arsenic areas of Taiwan [8], and sig-
nificantly elevated SMRs were also reported from nephri-
tis and nephrosis in Utah men [17]. Few mechanisms of
arsenic-induced kidney diseases have been proposed,
however. Kidney diseases are a frequent complication of
diabetes, and arsenic may be affecting the kidney via vas-
cular changes associated with diabetes.
In addition to diabetes and kidney diseases, elevated mor-
tality rates were observed for cerebrovascular diseases for
males (SMR, 1.19; 99%CI, 1.14–1.25) and females (SMR,
1.19; 99%CI, 1.15–1.23). Elevated mortality rates were
also observed when grouping together all diseases of the
circulatory system, however, only mortality from cere-
brovascular diseases was consistently elevated for both
males and females when examining the individual major
causes of vascular-related death. Cerebrovascular diseases
are the third leading cause of death in the United States
[35]. Epidemiologic studies have previously reported
increased prevalence [12] and mortality [8] from cere-
brovascular diseases in high arsenic areas of Taiwan.
Chiou et al. [12] found prevalence of cerebrovascular dis-
Table 3: Standardized Mortality Ratios in Genesee County, Michigan, 1979–1997.
Cause of Death ICD-9 Males Females
Obs SMR 99% CI Obs SMR 99% CI
Cancers
Colon and rectum 153–154 814 1.04 0.95–1.14 800 1.02 0.93–1.11
Liver and biliary Passages 155–156 150 0.84 0.67–1.03 171 1.00 0.82–1.22
Trachea, bronchus and lung 162 2,763 1.10* 1.04–1.15 1,526 1.13* 1.06–1.21
Skin melanoma 172 85 1.07 0.80–1.41 48 0.90 0.60–1.30
Other skin cancer 173 43 1.61* 1.05–2.36 11 0.76 0.30–1.58
Female reproductive organs 179–184 804 1.15* 1.05–1.26
Prostate 185 787 0.98 0.90–1.08
Bladder 188 209 1.05 0.87–1.25 101 0.99 0.75–1.27
Kidney and other urinary organs 189 182 1.04 0.85–1.26 119 1.04 0.81–1.31
Circulatory diseases
All diseases of the circulatory system 390–459 15,033 1.14* 1.12–1.17 15,863 1.16* 1.14–1.19
Essential hypertension and hypertensive renal disease 401, 403 139 1.31* 1.04–1.63 160 1.04 0.84–1.27
Hypertensive heart disease and hypertensive heart and renal disease 402, 404 311 1.07 0.92–1.24 427 1.12 0.99–1.27
Ischemic heart Diseases 410–414 7,981 1.05* 1.02–1.08 7,589 1.05* 1.02–1.08
Cerebrovascular diseases 430–438 1,893 1.15* 1.08–1.22 2,815 1.14* 1.09–1.20
Diseases of arteries arterioles and capillaries (DAAC) 440–448 669 1.02 0.92–1.12 760 1.04 0.95–1.14
Atherosclerosis 440 300 1.09 0.93–1.26 510 1.14* 1.01–1.27
Aortic aneurysm 441 257 0.89 0.76–1.05 115 0.75* 0.58–0.95
Respiratory diseases
All diseases of the respiratory system 460–519 2,522 1.08* 1.03–1.14 2,235 1.11* 1.05–1.17
Emphysema 492 373 1.09 0.95–1.25 250 1.18 1.00–1.39
Chronic airways Obstruction 496 985 1.23* 1.14–1.34 725 1.27* 1.16–1.40
Other diseases
Diabetes mellitus 250 737 1.30* 1.18–1.43 979 1.28* 1.17–1.38
Chronic liver diseases and cirrhosis 571 343 0.58* 0.50–0.66 268 0.89 0.75–1.03
Kidney diseases 580–589 335 1.21* 1.04–1.39 418 1.40* 1.23–1.58
ICD-9 = International Classification of Diseases, 9th Revision; Obs = Number of observed deaths; CI = confidence interval; *p < 0.01.Page 6 of 11
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low as 0.1–50 μg/L in drinking water (compared to a base-
line of <0.1 μg/L). Increased mortality from cerebrovascu-
lar diseases, however, was not found in previous ecologic
studies of health effects from low-to-moderate arsenic
exposure in the US [10,17]. Experimental studies suggest
potential mechanisms for cerebrovascular toxicity of
arsenic include inflammatory and coagulatory activity of
endothelial cells, increased oxidative stress, and impaired
vascular nitric oxide homeostatis [38]. These studies,
however, have typically been performed using unrealisti-
cally high arsenic concentrations calling into question
their mechanistic relevance [39]. Our study lends support
to the evidence that low-to-moderate levels of arsenic in
drinking water are associated with elevated rates of cere-
brovascular diseases.
Mixed results were observed for several other circulatory
disease outcomes across the six county, five county, and
Genesee County-only analyses. Deaths from atherosclero-
sis were significantly elevated and deaths from aortic
aneurysm were significantly reduced for females in the six
county and Genesee County-only analyses, but not in the
five county analyses. Deaths from ischaemic heart dis-
eases (for males and females) and essential hypertension
and hypertensive renal disease (for males only) were ele-
vated only in the Genesee County-only analyses. In only
the five county analyses, deaths from hypertensive heart
disease and hypertensive heart and renal disease were
reduced for males and females. Taken as a whole, these
results suggest that, with the exception of cerebrovascular
diseases, deaths from different types of circulatory dis-
eases were elevated in Genesee County but not in the
other five counties.
Differences in cancer and respiratory outcomes were also
detected between Genesee County and the other five
counties. In Genesee county, elevated mortality rates were
observed for trachea, bronchus, and lung cancer (for
males and females), other skin cancer (for males), cancer
of the female reproductive organs, all diseases of the res-
piratory system (for males and females), and chronic air-
ways obstruction (for males and females). None of these
disease outcomes were significantly elevated in the five
county analyses, and mortality rates were significantly
reduced for cancers of the trachea, bronchus, and lung (for
males and females), emphysema (for females), and all
diseases of the respiratory system (for females).
These differences in mortality profiles between Genesee
County and the other five counties may reflect differences
commonly observed between urban and rural residents.
Table 4: Standardized Mortality Ratios in Five Counties of Study Area Excluding Genesee County, Michigan, 1979–1997.
Cause of Death ICD-9 Males Females
Obs SMR 99% CI Obs SMR 99% CI
Cancers
Colon and rectum 153–154 625 1.04 0.93–1.15 569 1.05 0.94–1.17
Liver and biliary Passages 155–156 111 0.88 0.68–1.12 129 1.09 0.86–1.36
Trachea, bronchus and lung 162 1,662 0.91* 0.85–0.97 771 0.85* 0.77–0.93
Skin melanoma 172 58 0.88 0.61–1.23 43 1.06 0.69–1.56
Other skin cancer 173 16 0.77 0.36–1.41 15 1.47 0.67–2.76
Female reproductive organs 179–184 496 1.05 0.93–1.17
Prostate 185 661 1.08 0.98–1.20
Bladder 188 139 0.82 0.65–1.02 70 0.97 0.70–1.31
Kidney and other urinary organs 189 143 1.07 0.86–1.33 75 0.93 0.68–1.25
Circulatory diseases
All diseases of the circulatory system 390–459 10,874 1.06* 1.04–1.09 10,836 1.12* 1.10–1.15
Essential hypertension and hypertensive renal disease 401, 403 64 0.92 0.65–1.26 90 0.95 0.71–1.24
Hypertensive heart disease and hypertensive heart and renal disease 402, 404 87 0.53* 0.40–0.70 185 0.82* 0.67–0.98
Ischemic heart diseases 410–414 6,092 0.97 0.94–1.00 4,984 0.94* 0.91–0.98
Cerebrovascular diseases 430–438 1,600 1.25* 1.17–1.33 2,195 1.26* 1.19–1.33
Diseases of arteries arterioles and capillaries (DAAC) 440–448 551 0.99 0.88–1.10 569 1.04 0.93–1.16
Atherosclerosis 440 223 0.92 0.77–1.09 374 1.08 0.94–1.23
Aortic aneurysm 441 247 1.02 0.86–1.20 97 0.88 0.67–1.14
Respiratory diseases
All diseases of the respiratory system 460–519 1,911 1.01 0.95–1.07 1,333 0.91* 0.85–0.98
Emphysema 492 259 0.89 0.75–1.04 113 0.71* 0.55–0.90
Chronic airways Obstruction 496 721 1.08 0.98–1.19 409 0.96 0.84–1.09
Other diseases
Diabetes mellitus 250 512 1.24* 1.10–1.39 633 1.26* 1.14–1.40
Chronic liver diseases and cirrhosis 571 289 0.82* 0.70–0.96 148 0.86 0.68–1.05
Kidney diseases 580–589 279 1.37* 1.16–1.59 261 1.35* 1.15–1.58
ICD-9 = International Classification of Diseases, 9th Revision; Obs = Number of observed deaths; CI = confidence interval; *p < 0.01.Page 7 of 11
(page number not for citation purposes)
Environmental Health 2007, 6:4 http://www.ehjournal.net/content/6/1/4Approximately 21% of the population in Genesee county
resides in rural areas, compared with more than 80% in
the other five counties (Table 1). Farmers and rural resi-
dents have been shown to have lower mortality due to all
causes combined, all cancers combined, respiratory sys-
tem cancer, cardiovascular disease, and respiratory dis-
eases other than cancer compared to non-farmers and
urban residents [40-44]. A lower prevalence of smoking
among farmers compared with non-farmers is often cited
as one explanation for the lower mortality among the
former population [41-43]. A lower smoking prevalence
among our study population may also be a factor sup-
pressing mortality within the five county area, especially
since smoking is a key risk factor for many of the diseases
in question. Although data were not available on histori-
cal smoking prevalence for this population or for Michi-
gan, a comparison of data from the 1976 National Health
Interview Survey with a previous cohort study conducted
in the region in the 1970s indicated that proportionally
fewer adults in the region were smokers (25.1%) com-
pared with the adult white national population (36.0%)
[45,46]. These differences suggest that results which
appear to be consistent across the six county, five county,
and Genesee-county analyses are likely to be the least con-
founded.
Aside from potential differences in historical smoking
behaviors among the rural segment of the population,
additional differences between the six county study area
and the remainder of the state of Michigan deserve com-
ment (Table 5). Michigan Behavioral Risk Factor Survey
(BRFS) data from 1989–1993 indicate lower age-adjusted
rates of heavy or binge drinking from this part of Michi-
gan, as compared to the state as a whole [47]. This may
explain the reduced mortality rates observed for chronic
liver diseases and cirrhosis, which were consistent for
males across the different analyses.  Nevertheless, it is pos-
sible that low-to-moderate levels of arsenic in drinking
water are protective against liver diseases, although this
would be surprising since arsenic is a well-established risk
factor for liver diseases when high doses are given in ani-
mal studies [48].
The proportion of the population that lived in the same
county five years earlier was slightly higher in the six
county study area (87%) compared with the remainder of
the state (83%) (Table 1). The six county study area also is
considerably more rural than the State as a whole (Table
1). BRFS data generally indicate poorer access to health
care in the most rural parts of the State [47], however
higher rates of mammography and cholesterol screening
were reported in this part of Michigan compared with the
State average (Table 5). It is unknown how these rates
relate to screening for other diseases. A slightly higher
prevalence of cardiovascular disease risk factors such as
obesity, high blood pressure, and high cholesterol has
also been reported in the study area. Smoking prevalence
in the study area in the early 1990s, however, is no differ-
ent than that of the state as a whole. Obesity, high blood
pressure, cigarette smoking, and poor access to health care
are established risk factors for the diseases of strongest sig-
nificance here [49,50], however not all of these factors are
elevated throughout the study area. In addition, high
blood pressure may not be a confounder, but rather could
be an intermediate variable in cerebrovascular mortality.
Results indicate that deaths due to diseases strongly asso-
ciated with these risk factors, such as emphysema, lung
cancer, ischemic heart diseases, and DAAC were not ele-
vated throughout our study area, suggesting that smoking,
poor access to health care, obesity, and high blood pres-
sure can only partially explain the elevated mortality rates
observed for kidney and cerebrovascular diseases and dia-
betes mellitus.
In light of the attention given to arsenic and cancer [3-7],
the lack of findings in our study of significantly elevated
mortality rates for cancers of the bladder, kidney, lung,
and skin is intriguing. The SMR for lung cancer was ele-
vated in Genesee County, but depressed in the other five
counties. This may be due to a possible synergism
between arsenic and smoking [51], as Genesee is the most
urban county, presumably with the highest smoking rates
[41-43]. An alternative explanation for the lack of strong
cancer-related findings may be that arsenic levels in
groundwater of southeastern Michigan are below the
Table 5: Prevalence of Selected Behavioral Characteristics for Six County Study Area and Entire State of Michigan.
Six County Study Area Entire State of Michigan
Current smoking 25.1% 25.1%
Heavy drinking (60+ drinks/mo) 2.6% 3.7%
Binge drinking (5+ drinks on 1+ occasions in past month) 7.6% 11.7%
Cholesterol never checked 16.1% 19.3%
Ever told cholesterol high (among tested) 37.4% 33.0%
Ever told high blood pressure 33.6% 31.4%
Overweight (BMI >= 27.8 for men, >= 27.3 for women) 34.6% 33.4%
Never had mammogram (among women 40+) 19.0% 22.2%
From Michigan Behavioral Risk Factor Survey, 1989–1993; age-adjusted.Page 8 of 11
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ing factors which were not considered here. However, if
the excess risk for these cancers is small, it is possible that
ecologic studies will be unable to detect significant risk, as
was cautioned by the NRC subcommittee on Arsenic in
Drinking Water [52](see page 223). In addition, the use of
mortality rates may not be the best measure for certain
cancer outcomes, such as skin and bladder cancer, which
have relatively high survival rates [53].
In interpreting results of this ecologic analysis, other
aspects of the study deserve consideration. This study did
not assess the accuracy and precision of the arsenic labo-
ratory measurements nor the proportion of each arsenic
species (As(III) and As(V)) in the drinking water samples.
Private wells were preferentially sampled based on home-
owner requests, possibly causing an overestimate of pop-
ulation-based arsenic exposure, as has been shown in
another region of the US [54]. This study also did not
investigate differences in the reporting and classification
of underlying causes of death across counties and regions.
Such reporting and classification differences are common
in mortality studies of diabetes; however, these differences
are less common for mortality studies of kidney and cere-
brovascular diseases [55].
Additional limitations characteristic of ecologic studies
also need to be kept in mind when interpreting our
results: individual-level exposure has not been assessed;
mortality in one geographic area does not imply that a
person lived there for long periods of his or her life; and
confounding variables such as smoking and obesity were
not included in the quantitative analyses. Since there is no
individual-level exposure assessment, interpretation of
exposure at the individual-level would result in the Berk-
son measurement error [52]. Furthermore, as is fore-
warned by the ecologic fallacy, conclusions should not be
drawn at the individual-level because there was no indi-
vidual-level assessment of the exposure-disease relation-
ship, only a county-level assessment.
Conclusion
These limitations not withstanding, this region of south-
eastern Michigan was selected because of moderately ele-
vated concentrations of arsenic in groundwater, a large
percentage of the population using groundwater as their
drinking water source, and low rates of migration in and
out of the study area [30]. Health risks from long-term
ingestion of water containing arsenic concentrations in
the 10–100 μg/L range are uncertain, and this ecologic
study is a first step in suggesting that moderately elevated
arsenic concentrations are associated with mortality from
cerebrovascular diseases, diabetes mellitus, and kidney
diseases. Carefully planned individual-level epidemio-
logic studies are necessary to further investigate this rela-
tionship.
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